633 related articles for article (PubMed ID: 20172849)
21. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
22. A randomized, parallel, open-label study to compare once-daily sevelamer carbonate powder dosing with thrice-daily sevelamer hydrochloride tablet dosing in CKD patients on hemodialysis.
Fishbane S; Delmez J; Suki WN; Hariachar SK; Heaton J; Chasan-Taber S; Plone MA; Moe S
Am J Kidney Dis; 2010 Feb; 55(2):307-15. PubMed ID: 20042256
[TBL] [Abstract][Full Text] [Related]
23. High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients.
Jean G; Terrat JC; Vanel T; Hurot JM; Lorriaux C; Mayor B; Chazot C
Nephrol Dial Transplant; 2009 Sep; 24(9):2792-6. PubMed ID: 19395730
[TBL] [Abstract][Full Text] [Related]
24. Vascular calcification in patients with end-stage renal disease.
Floege J; Ketteler M
Nephrol Dial Transplant; 2004 Aug; 19 Suppl 5():V59-66. PubMed ID: 15284362
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and side-effect profile of sevelamer hydrochloride used in combination with conventional phosphate binders.
Sturtevant JM; Hawley CM; Reiger K; Johnson DW; Campbell SB; Burke JR; Bofinger A; Isbel NM
Nephrology (Carlton); 2004 Dec; 9(6):406-13. PubMed ID: 15663645
[TBL] [Abstract][Full Text] [Related]
26. [Either calcium carbonate or sevelamer decreases urinary oxalate excretion in chronic renal failure patients].
Caravaca F; Ruiz AB; Escola JM; Hernández Gallego R; Cerezo I; Fernández N; Barroso S; Martín MV
Nefrologia; 2007; 27(4):466-71. PubMed ID: 17944584
[TBL] [Abstract][Full Text] [Related]
27. Sevelamer worsens metabolic acidosis in hemodialysis patients.
De Santo NG; Frangiosa A; Anastasio P; Marino A; Correale G; Perna A; Di Stazio E; Stellato D; Santoro D; Di Meglio E; Iacono G; Ciacci C; Savica V; Cirillo M
J Nephrol; 2006; 19 Suppl 9():S108-14. PubMed ID: 16736432
[TBL] [Abstract][Full Text] [Related]
28. Sevelamer revisited: pleiotropic effects on endothelial and cardiovascular risk factors in chronic kidney disease and end-stage renal disease.
Rastogi A
Ther Adv Cardiovasc Dis; 2013 Dec; 7(6):322-42. PubMed ID: 24327730
[TBL] [Abstract][Full Text] [Related]
29. Long-term sevelamer treatment lowers serum fibroblast growth factor 23 accompanied with increasing serum Klotho levels in chronic haemodialysis patients.
Lin HH; Liou HH; Wu MS; Lin CY; Huang CC
Nephrology (Carlton); 2014 Nov; 19(11):672-8. PubMed ID: 25113414
[TBL] [Abstract][Full Text] [Related]
30. Chronic inflammation and mortality in haemodialysis: effect of different renal replacement therapies. Results from the RISCAVID study.
Panichi V; Rizza GM; Paoletti S; Bigazzi R; Aloisi M; Barsotti G; Rindi P; Donati G; Antonelli A; Panicucci E; Tripepi G; Tetta C; Palla R;
Nephrol Dial Transplant; 2008 Jul; 23(7):2337-43. PubMed ID: 18305316
[TBL] [Abstract][Full Text] [Related]
31. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients: results of a randomized clinical trial.
Suki WN;
J Ren Nutr; 2008 Jan; 18(1):91-8. PubMed ID: 18089452
[TBL] [Abstract][Full Text] [Related]
32. Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients.
Koiwa F; Kazama JJ; Tokumoto A; Onoda N; Kato H; Okada T; Nii-Kono T; Fukagawa M; Shigematsu T;
Ther Apher Dial; 2005 Aug; 9(4):336-9. PubMed ID: 16076378
[TBL] [Abstract][Full Text] [Related]
33. Study on the relationship of serum fetuin-A concentration with aortic stiffness in patients on dialysis.
Hermans MM; Brandenburg V; Ketteler M; Kooman JP; van der Sande FM; Gladziwa U; Rensma PL; Bartelet K; Konings CJ; Hoeks AP; Floege J; Leunissen KM
Nephrol Dial Transplant; 2006 May; 21(5):1293-9. PubMed ID: 16396973
[TBL] [Abstract][Full Text] [Related]
34. New strategy to attenuate pulse wave velocity in haemodialysis patients.
Takenaka T; Suzuki H
Nephrol Dial Transplant; 2005 Apr; 20(4):811-6. PubMed ID: 15772266
[TBL] [Abstract][Full Text] [Related]
35. Sevelamer decreases systemic inflammation in parallel to a reduction in endotoxemia.
Stinghen AE; Gonçalves SM; Bucharles S; Branco FS; Gruber B; Hauser AB; Pecoits-Filho R
Blood Purif; 2010; 29(4):352-6. PubMed ID: 20357435
[TBL] [Abstract][Full Text] [Related]
36. Impact of fibroblast growth factor 23 on lipids and atherosclerosis in hemodialysis patients.
Ashikaga E; Honda H; Suzuki H; Hosaka N; Hirai Y; Sanada D; Nakamura M; Nagai H; Matsumoto K; Kato N; Mukai M; Watanabe M; Takahashi K; Shishido K; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):315-22. PubMed ID: 20609185
[TBL] [Abstract][Full Text] [Related]
37. Ankle brachial index as a predictor for mortality in patients with chronic kidney disease and undergoing haemodialysis.
Chen SC; Chang JM; Hwang SJ; Tsai JC; Liu WC; Wang CS; Lin TH; Su HM; Chen HC
Nephrology (Carlton); 2010 Apr; 15(3):294-9. PubMed ID: 20470297
[TBL] [Abstract][Full Text] [Related]
38. [Treatment of hyperphosphatemia with sevelamer in patients with chronic renal failure].
Suñer M; Guerrero A; Montes R; Rivera M; Ruiz A; Martínez-García M; Pérez-Valdivia MA; Mateos J
Nefrologia; 2004; 24(2):142-8. PubMed ID: 15219089
[TBL] [Abstract][Full Text] [Related]
39. Prospective randomized multicenter trial of sevelamer hydrochloride and calcium carbonate for the treatment of hyperphosphatemia in hemodialysis patients in Japan.
Koiwa F; Onoda N; Kato H; Tokumoto A; Okada T; Fukagawa M; Shigematsu T;
Ther Apher Dial; 2005 Aug; 9(4):340-6. PubMed ID: 16076379
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of sevelamer. Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients.
Shaheen FA; Akeel NM; Badawi LS; Souqiyyeh MZ
Saudi Med J; 2004 Jun; 25(6):785-91. PubMed ID: 15195212
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
